Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Rat, Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||A synthetic peptide aa 1-29 (MAN-SASPEQNQNHCSAINNSIPLMQGNLPY) from the N-terminal of human GnRH receptor|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay Dependent|
|Immunofluorescence (IF)||Assay Dependent|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-11538 targets GnRH Receptor in FACS, IF, and IHC (P) applications and shows reactivity with Human samples.
The MA5-11538 immunogen is a synthetic peptide aa 1-29 (MAN-SASPEQNQNHCSAINNSIPLMQGNLPY) from the N-terminal of human GnRH receptor.
GnRH receptor contains seven hydrophobic transmembrane domains connected by hydrophilic extracellular and intracellular loops characteristic of G-protein coupled receptors. GnRH stimulates the gonadotrophs of the anterior pituitary to secrete luteinizing hormone (LH) as well as follicle-stimulating hormone (FSH).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth.
MA5-11538 was used in western blot to evaluate the effect of degarelix on human prostate cell growth
|Sakai M,Martinez-Arguelles DB,Patterson NH,Chaurand P,Papadopoulos V||PloS one (10:null)||2015|
Gonadotropin-releasing hormone-II increases membrane type I metalloproteinase production via beta-catenin signaling in ovarian cancer cells.
MA5-11538 was used in western blot to study the role of beta-catenin signaling in the induction of MT1-MMP expression in ovarian cancer cells by gonadotropin-releasing hormone-II
|Ling Poon S,Lau MT,Hammond GL,Leung PC||Endocrinology (152:764)||2011|
Presence of immunoreactive gonadotropin releasing hormone (GnRH) and its receptor (GnRHR) in rat ovary during pregnancy.
MA5-11538 was used in western blot to investigate the expression of gonadotropin releasing hormone and its receptor in the ovaries during pregnant rats
|Sengupta A,Chakrabarti N,Sridaran R||Molecular reproduction and development (75:1031)||2008|
Emerging association between androgen deprivation therapy and male meningioma: significant expression of luteinizing hormone-releasing hormone receptor in male meningioma.
MA5-11538 was used in immunohistochemistry - paraffin section to determine the expression of LHRH receptor, progesterone receptor, and Ki67 labeling index in patients with meningioma
|Li Q,Coulson H,Klaassen Z,Sharma S,Ramalingam P,Moses KA,Terris MK||Prostate cancer and prostatic diseases (16:387)||2013|
GnRH receptor; gnRH-R; gonadotropin-releasing hormone (type 1) receptor 1; Gonadotropin-releasing hormone receptor; leutinizing hormone releasing horomone receptor; leutinizing-releasing hormone receptor; luliberin receptor; type I GnRH receptor
GNRHR; GNRHR1; GRHR; HH7; LHRHR; LRHR